Jason Fontenot, PhD, on Overcoming the Challenge of Delivery for Zinc Finger Epigenetic Repressors

Video

The chief scientific officer of Sangamo Therapeutics discussed the company’s AAV capsid evolution research.

“Our vision is that we can use our [ZF] platform to repress the tau protein, which is implicated in Alzheimer disease progression in a once-and-done way to essentially stop the progression of Alzheimer disease. It has huge potential for a huge population of people.”

Although investigational genomic medicines have shown great potential for treating a wide range of diseases, delivering these therapies to target tissues remains a challenge, especially in neurological indications such as Alzheimer disease. As such, the identification of new delivery tools, such as novel adeno-associated virus capsids, is of particular interest.

Sangamo Therapeutics presented several posters covering its research into AAV capsid evolution at the American Society of Gene and Cell Therapy (ASGCT) 2023 Annual Meeting, held May 16-20, in Los Angeles, California. A goal of the work is to identify capsids suitable for widespread delivery of genomic medicines throughout the brain, as this distribution is likely necessary to effectively treat conditions such as Alzheimer disease and Parkinson disease.

In an interview with CGTLive™, Jason Fontenot, PhD, the chief scientific officer of Sangamo Therapeutics, discussed the company’s methods for capsid evolution and how the work goes hand in hand with the company’s research into zinc finger (ZF) genome regulation, which could provide the possibility of treating conditions such as these by regulating the expression of relevant genes. He noted that although the company’s initial 2 programs for ZF epigenetic repression focus on conditions which are more straightforward to target with currently available AAV delivery methods, namely NaV1.7-associated small fiber neuralgia and Creutzfeldt-Jakob disease, the targeting of Alzheimer disease is an important longer-term goal for the company. He also briefly touched on the importance of in vivo studies as a milestone in the development of its 2 preclinical ZF genome regulation programs and expressed optimism about future synergy between the company’s ZF platform and the capsid evolution research.

REFERENCE
1. Sangamo Therapeutics to present pre-clinical data from its genomic engineering platform at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT). News release. Sangamo Therapeutics, Inc. May 2, 2023. Accessed May 18, 2023. https://investor.sangamo.com/news-releases/news-release-details/sangamo-therapeutics-present-pre-clinical-data-its-genomic
Related Videos
Deepak L. Bhatt, MD, MPH, MBA
Jeffrey Chamberlain, PhD, on Bringing Back the Focus to Basic Research for ASGCT 2024
Amit Soni, MD, the Center for Inherited Blood Disorders
Jonathan W. Weinsaft, MD, Future Research With Gene Therapy for Cardiovascular Disease
Amit Soni, MD, the Center for Inherited Blood Disorders
Omid Hamid, MD
Paula Cannon, PhD, the president elect of ASGCT and a distinguished professor of microbiology at Keck School of Medicine of USC
George Tachas, PhD
Alexandra Gomez-Arteaga, MD
Pietro Genovese, PhD, the principal investigator at the Gene Therapy Program of Dana-Farber/Boston Children’s Cancer and Blood Disorder Center
Related Content
© 2024 MJH Life Sciences

All rights reserved.